Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neugranin vs Pegfilgrastim in Breast Cancer
NCT01126190Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jun 2010
- Primary completion
- Feb 2012
- Modality
- Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 3 trial of balugrastim in chemotherapy-induced neutropenia (CIN), sponsored by Teva Pharmaceutical Industries Ltd.. Started Jun 2010; status: completed.
02
Drugs
balugrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT01126190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01126190.